Michela Palmieri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michela Palmieri has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Charles A. O'BRien
Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America; Division of Endocrinology, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America; Department of Orthopaedic Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America; Central Arkansas Veterans Healthcare System, Little Rock, AR, United States of America
57 shared publications - Elena Ambrogini
Affiliations Department of Internal Medicine, Division of Endocrinology and Metabolism and Center for Musculoskeletal Disease Research, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America, Department of Veterans Affairs, Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States of America, Department of Orthopedic Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America
57 shared publications - Intawat Nookaew
University of Arkansas for Medical Sciences
57 shared publications - Jesus Delgado-Calle
Department of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, USA
57 shared publications - Maria Almeida
University of Arkansas for Medical Sciences
57 shared publications - Aric Anloague
Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
56 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by Elsevier in SSRN Electronic Journal
Wnt10b is required for the increase in cancellous bone caused by oxidized phospholipids blockade
Oxidized phospholipids containing phosphatidylcholine (PC-OxPLs), present on oxidized low-density lipoproteins (OxLDL) and apoptotic cells, are pathogenic in osteoporosis. PC-OxPLs are bound by the IgM E06 antibody, which blocks their deleterious effects. Overexpression of the antigen-binding domain of E06 (E06-scFv) increases bone mass in 6-month-old mice and attenuates high fat diet- and age-induced bone loss by increasing osteoblast number and function. The mechanisms mediating the anabolic effect of oxidized phospholipids blockade are unclear. In previous work, we showed that E06-scFv upregulates the expression of Wnt10b and Wnt signaling in vivo. We report herein that the bulk of Wnt10b in the bone microenvironment originates from osteoblast lineage cells. OxLDL decreases the expression of Wnt10b and Wnt target genes in osteoblastic cells, and single cell RNA-sequencing (scRNA-seq) of mesenchymal cells reveals an increase in Wnt10b and Wnt target genes in pre-osteoblasts and osteoblasts of E06-scFv transgenic mice compared to WT. Loss of Wnt10b prevents the increases in BMD by DXA and in vertebral and femoral cancellous bone in 6-month-old E06-scFv transgenic male mice, and attenuates these increases in female mice. Collectively, these findings indicate that oxidized phospholipids decrease bone mass, at least in part, by suppressing Wnt10b.
- 9 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessWnt10b is required for the increase in cancellous bone caused by oxidized phospholipids blockade
Oxidized phospholipids containing phosphatidylcholine (PC-OxPLs), present on oxidized low-density lipoproteins (OxLDL) and apoptotic cells, are pathogenic in osteoporosis. PC-OxPLs are bound by the IgM E06 antibody, which blocks their deleterious effects. Overexpression of the antigen-binding domain of E06 (E06-scFv) increases bone mass in 6-month-old mice and attenuates high fat diet- and age-induced bone loss by increasing osteoblast number and function. The mechanisms mediating the anabolic effect of oxidized phospholipids blockade are unclear. In previous work, we showed that E06-scFv upregulates the expression of Wnt10b and Wnt signaling in vivo. We report herein that the bulk of Wnt10b in the bone microenvironment originates from osteoblast lineage cells. OxLDL decreases the expression of Wnt10b and Wnt target genes in osteoblastic cells, and single cell RNA-sequencing (scRNA-seq) of mesenchymal cells reveals an increase in Wnt10b and Wnt target genes in pre-osteoblasts and osteoblasts of E06-scFv transgenic mice compared to WT. Loss of Wnt10b prevents the increases in BMD by DXA and in vertebral and femoral cancellous bone in 6-month-old E06-scFv transgenic male mice, and attenuates these increases in female mice. Collectively, these findings indicate that oxidized phospholipids decrease bone mass, at least in part, by suppressing Wnt10b.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 16 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 16 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 16 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 16 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 6 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 6 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 6 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 6 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 4 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 4 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 4 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 4 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 9 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 9 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 9 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 9 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 7 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 7 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 7 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 7 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary figure 10 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 10 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary figure 10 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
Supplementary figure 10 from Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis